Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ivosidenib plus azacitidine in previously untreated IDH1-mutated acute myeloid leukemia
MOH_2018-02-19_002199Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Placebo + azacitidine with Ivosidenib + azacitidine (2 arms). Primary endpoint: Overall survival. Started Jul 2017; status: completed.
02
Drugs
ivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2018-02-19_002199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-19_002199.